Company / Cash & Equivalents
PLUS THERAPEUTICS, INC. Cash & Equivalents History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$4.3M
FY2025
5-year range
$76.0K / $14.3M
FY2021-FY2025
Trend
+5500.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +5500% YoY in FY2025, a notable deviation from the 9-year average annual change of +622%.
Based on SEC 10-K filings.
$4M in FY2025 with a 10-year CAGR of -11.6%.
Declined from $13M to $4M over the past 7 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -11.6%
Key checks
Key Insights
- In FY2025, cash & equivalents increased 5500.0% year-over-year.
- Peak cash & equivalents was recorded in FY2012.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -2.46 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.3M | +5500.0% |
| FY2024 | $76.0K | -99.4% |
| FY2018 | $12.6M | +0.3% |
| FY2017 | $12.6M | -12.4% |
| FY2016 | $14.3M | -1.9% |
| FY2015 | $14.6M | -43.1% |
| FY2014 | $25.7M | -30.3% |
| FY2013 | $36.9M | -29.9% |
| FY2012 | $52.7M | +317.6% |
| FY2011 | $12.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026